Sol Gel Technolg - SLGL STOCK NEWS

Sol-Gel Technologies (NASDAQ: SLGL) reported third-quarter 2020 revenues of $2.1 million, driven by generic product sales, with expectations of a revenue decrease due to increased competition. The FDA has accepted the New Drug Application (NDA) for Epsolay, targeting rosacea, with a PDUFA goal date of April 26, 2021. Additionally, an NDA for Twyneo has been submitted for acne treatment. The company reported a net loss of $8.6 million and has $57.3 million in cash and marketable securities, sufficient to fund operations through the third quarter of 2021.

Sol-Gel Technologies (NASDAQ: SLGL) announced its participation in two upcoming virtual investor conferences. The first is the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020, at 8:30 AM ET, featuring CEO Dr. Alon Seri-Levy. The second is the Jefferies Virtual London Healthcare Conference on November 18, 2020, at 5:00 PM GMT, with several executives, including CFO Gilad Mamlok. Webcasts of the presentations will be accessible on the company’s website.

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL) will announce its third quarter 2020 financial results on November 12, 2020, at 7:05 AM ET. The company is a clinical-stage dermatology firm that specializes in developing branded and generic topical products for skin diseases. Their innovative microencapsulation technology is being used for products such as Twyneo and Epsolay, which are under investigation for acne vulgaris and papulopustular rosacea, respectively. Other pipeline projects include SGT-210, tapinarof, and roflumilast.

Sol-Gel Technologies (NASDAQ: SLGL) announced the FDA's acceptance of its New Drug Application (NDA) for Epsolay®, a topical cream targeting inflammatory lesions in rosacea. The PDUFA goal date is set for April 26, 2021, which could make Epsolay the first FDA-approved single-agent benzoyl peroxide prescription product. Results from Phase 3 trials, involving 733 patients, showed significant improvements in treatment outcomes compared to the vehicle. The adverse reactions were mostly mild to moderate, indicating a favorable safety profile.

Sol-Gel Technologies (NASDAQ: SLGL), a clinical-stage dermatology company, announced participation in upcoming virtual investor conferences. CEO Dr. Alon Seri-Levy will provide a company overview, while CFO Gilad Mamlok will represent Sol-Gel at the H.C. Wainwright Healthcare Conference on September 15, 2020, at 10:00 AM ET. Additionally, a fireside chat featuring Dr. Seri-Levy, Mr. Mamlok, and John Vieira is scheduled for the Cantor Fitzgerald Virtual Global Healthcare Conference on September 17, 2020, at 8:40 AM ET. Webcasts will be available on the company's website.

On September 3, 2020, Sol-Gel Technologies (NASDAQ: SLGL) reported that Bausch Health initiated a patent infringement lawsuit regarding Perrigo's ANDA for a generic version of Duobrii® lotion, which treats plaque psoriasis. Perrigo's application, filed on July 23, asserts that certain patents are invalid or will not be infringed. Duobrii® had annual sales of $88.4 million as of July 2020. Sol-Gel collaborates with Perrigo, sharing development costs and profits from the potential commercialization of the generic product.

Sol-Gel Technologies (NASDAQ: SLGL) reported Q2 2020 financial results, achieving $1.1 million in revenue, primarily from a collaboration with Perrigo. The company submitted a New Drug Application for Epsolay, aimed at treating subtype II rosacea, and is on track for another NDA submission for Twyneo in H2 2020. R&D expenses decreased to $6.5 million, down from $11.4 million year-on-year, while general and administrative costs rose to $2.2 million. Sol-Gel reported a net loss of $7.1 million, up from $4.9 million in Q2 2019. The company holds $66 million in cash and marketable securities, sufficient to fund operations into Q3 2021.

Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a clinical-stage dermatology firm, is set to report its second quarter 2020 financial results on August 6, 2020, at 7:05 AM ET. The company focuses on developing branded and generic topical drugs for skin diseases, utilizing its proprietary microencapsulation technology. Key products include Twyneo for acne vulgaris and Epsolay for rosacea. The pipeline also features early-stage and preclinical assets targeting various skin conditions.

Sol-Gel Technologies (NASDAQ: SLGL) announced an anticipated FDA approval of a generic drug in Q2 2021, following a partnership agreement. The brand's sales exceeded $180 million in 2019, indicating significant market potential. This launch could establish a new revenue stream for Sol-Gel in 2021, enhancing its financial outlook. CEO Alon Seri-Levy expressed optimism about the brand's entry into the market, emphasizing its potential benefits for the company's growth.